A prospective observational study of combination of Clostridium butyricum therapy and immune checkpoint inhibitors for thoracic malignancies
Not Applicable
Recruiting
- Conditions
- Thoracic malingancies
- Registration Number
- JPRN-UMIN000043045
- Lead Sponsor
- Kumamoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in fecal microflora pre and post treatment with immune checkpoint inhibitors
- Secondary Outcome Measures
Name Time Method The following survival and safety analyses Progression free survival(PFS) 6 months PFS rate 1 year survival rate Overall survival Objective response rate Duration of response Safety (irAEs, diarrhea, etc.) Survival analysis of cases with antibiotic drugs Survival analysis of cases with proton pump inhibitor Analysis of the relationship with the results of food intake questionnaire